NASDAQ:LGVN

Longeveron Stock Insider Trading

Healthcare > Biotechnology

Buy LGVN

*Your capital is at risk

$0.702

+0.0262 (+3.88%)

At Close: Jul 31, 2026

Longeveron Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 89.44. In total, the insiders bought 5.57M and sold 408.16K LGVN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	89.44
● Buy	5.57M shares
● Sell	408.16K shares
68% Buy Activity Weak Positive Correlation
Buy Signal Medium Confidence Jul 06, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 89.44. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Aug 11, 2025 Buy	Warrant (right to buy)	Powell James Nathaniel Chief Executive Officer	CEO / President	44 115 Value: $37.5K
Aug 11, 2025 Buy	Class A Common Stock P-Purchase	Locklear Lisa Chief Financial Officer	C-Suite Officer	11 766 Value: $8K
Aug 11, 2025 Buy	Warrant (right to buy) P-Purchase	Locklear Lisa Chief Financial Officer	C-Suite Officer	29 415 Value: $25.0K
Aug 11, 2025 Buy	Class A Common Stock P-Purchase	Baluch Khoso Director	Director	11 766 Value: $8K
Aug 11, 2025 Buy	Warrant (right to buy) P-Purchase	Baluch Khoso Director	Director	29 415 Value: $25.0K
Aug 11, 2025 Buy	Warrant (right to buy) P-Purchase	Baluch Khoso Director	Director	29 415 Value: $25.0K
Aug 11, 2025 Buy	Class A Common Stock P-Purchase	Baluch Khoso Director	Director	11 766 Value: $8K
Aug 11, 2025 Buy	Warrant (right to buy) P-Purchase	Locklear Lisa Chief Financial Officer	C-Suite Officer	29 415 Value: $25.0K
Aug 11, 2025 Buy	Class A Common Stock P-Purchase	Locklear Lisa Chief Financial Officer	C-Suite Officer	11 766 Value: $8K
Jul 15, 2025 Buy	Stock Option (right to buy) A-Award	Hare Joshua Chief Scientific Officer	Officer	109 000 Value: $160.2K
Jul 15, 2025 Buy	Class A Common Stock A-Award	Soffer Rock Director	Director	17 000 Value: $25.0K
Jul 15, 2025 Buy	Class A Common Stock A-Award	Agafonova Nataliya Chief Medical Officer	Officer	102 000 Value: $149.9K
Jul 15, 2025 Buy	Stock Option (right to buy) A-Award	Agafonova Nataliya Chief Medical Officer	Officer	34 000 Value: $50.0K
Jul 15, 2025 Buy	Class A Common Stock A-Award	Hajjar Roger Joseph Director	Director	17 000 Value: $25.0K
Jul 15, 2025 Buy	Class A Common Stock A-Award	Lehr Paul T General Counsel, Secretary	Officer	102 000 Value: $149.9K
Jul 15, 2025 Buy	Stock Option (right to buy) A-Award	Lehr Paul T General Counsel, Secretary	Officer	34 000 Value: $50.0K
Jul 15, 2025 Buy	Class A Common Stock A-Award	Locklear Lisa Chief Financial Officer	C-Suite Officer	102 000 Value: $149.9K
Jul 15, 2025 Buy	Stock Option (right to buy) A-Award	Locklear Lisa Chief Financial Officer	C-Suite Officer	34 000 Value: $50.0K
Jul 15, 2025 Buy	Class A Common Stock A-Award	Blass Devin CTO & SVP Of Cmc	Officer	102 000 Value: $149.9K
Jul 15, 2025 Buy	Stock Option (right to buy) A-Award	Blass Devin CTO & SVP Of Cmc	Officer	34 000 Value: $50.0K
Jul 15, 2025 Buy	Class A Common Stock A-Award	Baluch Khoso Director	Director	17 000 Value: $25.0K
Jul 15, 2025 Buy	Class A Common Stock A-Award	Hashad Mohamed Wa'el Ahmed Chief Executive Officer	CEO / President	180 000 Value: $264.6K
Jul 15, 2025 Buy	Stock Option (right to buy) A-Award	Hashad Mohamed Wa'el Ahmed Chief Executive Officer	CEO / President	60 000 Value: $88.2K
Jul 15, 2025 Buy	Class A Common Stock A-Award	Kender Richard N Director	Director	17 000 Value: $25.0K
Jul 15, 2025 Buy	Class A Common Stock A-Award	Motwani Neha J. Director	Director	17 000 Value: $25.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT LONGEVERON INC.

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, a...

Read Full Profile Here